TrialNet

February 2, 2024

Study links small pancreas size to faster progression to stage 3 Type 1 diabetes

The study findings, published in the journal Diabetes Care, suggest that pancreas imaging can have a benefit in tracking disease development and recruitment for preventive and therapeutic trials.

By Jill Clendening
March 23, 2023

Study sheds light on drug’s impact on diabetes progression

A Vanderbilt study of a treatment to delay the development of Type 1 diabetes in individuals at high risk did not meet the study goals of delaying progression from normal glucose tolerance to abnormal glucose tolerance or clinical diagnosis, although the study drug, abatacept, impacted immune response and preserved insulin production during the one-year treatment period.

By Craig Boerner
William Russell, MD, second from right, is the principal investigator for a study that uses a plasmid-based therapy to try to selectively desensitize the immune system in people with Type 1 diabetes. Shown here are, from left, Lana Howard, RN, CCRP; Brenna Hammel, RN, CPN; study participant Adam Brooks; Russell; and Robin Perkins, RN. Not pictured: Faith Brendle, RN, CPN, CCRP.
September 1, 2022

Trial participant steps up to help advance diabetes research

Vanderbilt is one of 16 North American sites conducting the Tolerance Using Plasmid in People with Type 1 Diabetes (TOPPLE) study, a phase 1 investigation that tests the safety and dosing of a new plasmid therapy.

By Jill Clendening
June 9, 2019

Study drug delays type 1 diabetes in high risk children and adults

Drug delays onset of type 1 diabetes by two years

By Craig Boerner
Insulin in vials
September 10, 2015

Diabetes trial targets body’s ability to produce insulin

Kiersten Eaddy had long looked forward to her high school graduation day and joining her classmates to celebrate the accomplishment.

By VUMC News and Communications
September 12, 2013

VU tracking drug’s ability to prevent type 1 diabetes

Vanderbilt’s Eskind Diabetes Clinic has been selected to examine the ability of the drug abatacept to prevent type 1 diabetes (T1D). As part of the TrialNet consortium, Vanderbilt will be one of 14 North American sites observing the effects of the drug in people at high risk to develop T1D.

By VUMC News and Communications
July 31, 2012

National type I diabetes prevention trial now an option for younger children

A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old.
By Craig Boerner
January 5, 2012

Diabetes trial sets bar high for retaining research subjects

By VUMC News and Communications